October 2, 2012 (Berlin, Germany) — A new position statement for the treatment of type 2 diabetes takes an approach much more focused on the individual patient compared with the "one number fits all" ...
BOSTON--(BUSINESS WIRE)--POXEL SA (Euronext: POXEL), a biopharmaceutical company developing innovative drugs to treat type 2 diabetes, today presented data at the American Diabetes Association (ADA) ...
Objective: To evaluate antidiabetic drug treatment patterns and glycemic control among patients diagnosed with type 2 diabetes mellitus. Study Design: Retrospective study using the automated databases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback